Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BioMarin Buys LEAD Therapeutics of California and Shanghai

publication date: Feb 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioMarin Pharmaceutical of Novato, California, will acquire LEAD Therapeutics of San Bruno, California and Shanghai, a drug discovery company that has a strategic relationship with  ShangPharma, a CRO. ShangPharma has a scientific staff dedicated to doing LEAD’s chemistry work, and it has made an investment in ShangPharma. BioMarin will pay $18 million upfront and an additional $11 million when LEAD’s key compound files for IND. The deal could ultimately be worth $96 million with milestones. More details...

Stock Symbol: (NSDQ: BMRN)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners